# A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

> **NCT06719362** · PHASE1 · RECRUITING · sponsor: **Providence Health & Services** · enrollment: 110 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** M3T01
- **DRUG:** Pembrolizumab
- **RADIATION:** Chemoradiation
- **DRUG:** FOLFOX regimen

## Key facts

- **NCT ID:** NCT06719362
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2028-02
- **Final completion:** 2030-02
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06719362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06719362, "A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06719362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*